Aurobindo Pharma has received tentative approval from the US Food & Drug Administration for Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg (ANDA 200823). The product will be eligible for final approval upon the expiration of 180-day generic drug exclusivity.
Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets, 15mg (base)/500mg and 15mg (base)/850mg are the generic equivalent of Takeda Global Research Development Center Inc’s Actoplus Met Tablets, 15mg (base)/500mg and 15mg (base)/850mg. Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type-2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate. The product has a market size of approximately $ 433 Million for the twelve months ending March 2012 according to IMS.
The product has been approved out of Unit VII (SEZ) formulations facility in Hyderabad, India
The company now has a total of 159 ANDA approvals (134 Final approvals including 1 from Aurolife Pharma LLC and 25 tentative approvals) from USFDA
Aurobindo Pharma has a product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. The company is the market leader in semi-synthetic penicillin drugs.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1781.95 |
Dr. Reddys Lab | 1200.20 |
Cipla | 1487.35 |
Lupin | 2056.40 |
Zydus Lifesciences | 946.10 |
View more.. |